Subscribe

Endometrial Cancer

KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Lenvatinib plus pembrolizumab significantly improves progression-free and overall survival compared to chemotherapy among patients with advanced endometrial cancer.

GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer

The TC regimen demonstrated noninferiority to TAP in terms of OS and PFS while offering a better toxicity profile, making it a suitable first-line treatment for advanced endometrial cancer

GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

NRG-GY012

RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

NRG GY018: Pembrolizumab in Advanced Endometrial Cancer

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

DUO-E Trial

Does adding durvalumab (a PD-L1 inhibitor) and olaparib (a PARP inhibitor) to standard chemotherapy improve outcomes in advanced or recurrent endometrial cancer?

DESTINY-PanTumor02

Phase II study evaluating the role of HER2-directed ADC Trastuzumab deruxtecan (T-DxD)

Minimally Invasive Surgery in Endometrial Cancer

A systematic review and a meta-analysis supporting the safety of MIS in high-risk endometrial cancer